The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...
The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...
The US Food and Drug Administration (FDA) on Friday approved US pharma giant Pfizer’s Hympavzi (marstacimab-hncq) for routine ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.